Protecting the Health of Women Living with HIV: Ainuovirine Tablets and Ainuomiti Tablets are a new generation of anti-HIV drugs independently developed by a national anti-HIV innovative enterprise, Jiangsu Aidea Pharmaceutical Co., Ltd. (“Aidea Pharma”), and are praised as the "Anti-HIV Twin Stars".

At the INTEREST World HIV Conference scheduled to be held in Namibia, Africa in May 2025, the female subgroup study data from the Phase III trials of Ainuovirine Tablets (RACER study) and Ainuomiti Tablets (SPRINT study) will be presented to the world for the first time. This study has found that Ainuovirine Tablets and Ainuomiti Tablets are comparable to first-line therapies in virologic suppression among treatment-naïve and treatment-experienced (switch) women living with HIV , respectively. Aidea Pharma also pays special attention to the benefits of women living with HIV in terms of immune reconstitution, body weight, lipid metabolism, and neuropsychiatric safety, filling the evidence-based gap in clinical research on women living with HIV.